Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
2.
Ophthalmologe ; 112(9): 752-63, 2015 Sep.
Article in German | MEDLINE | ID: mdl-25833754

ABSTRACT

BACKGROUND AND PURPOSE: In September 2011 the cornea section of the German Ophthalmological Society (DOG) established the first German Acanthamoeba keratitis registry. The data of this multicenter survey are being collected, compiled and evaluated at the Department of Ophthalmology at the Saarland University. The aim of this article is to present an intermediate report. PATIENTS AND METHODS: Data from 172 eyes with Acanthamoeba keratitis were collected during the last 10 years. For this interim report we actually evaluated 121 eyes (60.2 % female patients, average age 41.3 years) and collected the following data: date of onset of symptoms, date and method of diagnosis, initial diagnosis, anamnestic data, clinical symptoms and signs at diagnosis and during follow-up, conservative and surgical therapy. Criteria for inclusion in the Acanthamoeba registry was the established diagnosis of an Acanthamoeba keratitis with at least one of the methods described in this article. RESULTS: Acanthamoeba keratitis could be histologically proven in 55.3 % of the cases, via PCR in 25.6 %, with confocal microscopy in 20.4 % and using in vitro cultivation in 15.5 %. Clinical symptoms and signs in Acanthamoeba keratitis were pain in 67.0 %, ring infiltrates in 53.4 %, pseudodendritiform epitheliopathy in 11.7 % and keratoneuritis in 5.8 %. In 47.6 % of the cases the initial diagnosis was herpes simplex virus keratitis followed by bacterial keratitis in 25.2 % and fungal keratitis in 3.9 %. Acanthamoeba keratitis was the correct initial diagnosis in only 23.2 % of cases. The average time period between first symptoms and diagnosis was 2.8 ± 4.0 months (range 0-23 months). A triple therapy with Brolene® Lavasept® and antibiotic eye drops at least 5 ×/day was used in 54.5 % of eyes (n = 66). Penetrating keratoplasty was performed in 40.4 %, in 18 cases in combination with cryotherapy of the cornea. The mean graft diameter was 7.9 ± 1.1 mm (range 3.5-11.0 mm). The final visual acuity (Snellen visual acuity chart at 5 m) was comparable in the two groups of eyes with (5/40 ± 5/25) and without (5/32 ± 5/25) keratoplasty. CONCLUSION: Acanthamoeba keratitis is a rare and often very late diagnosed disease and two thirds of the cases were initially misdiagnosed. The early recognition of the typical symptoms is crucial for the prognosis of the disease. All ophthalmological departments in Germany are invited to submit further data of all confirmed cases (berthold.seitz@uks.eu), whether retrospectively or prospectively in order to generate an adequate standardized diagnostic and therapeutic approach for this potentially devastating disease.


Subject(s)
Acanthamoeba Keratitis/diagnosis , Acanthamoeba Keratitis/therapy , Keratoplasty, Penetrating/statistics & numerical data , Registries , Symptom Assessment/statistics & numerical data , Acanthamoeba Keratitis/epidemiology , Female , Germany/epidemiology , Humans , Male , Pilot Projects , Prevalence , Risk Factors , Treatment Outcome
3.
Klin Monbl Augenheilkd ; 231(6): 636-9, 2014 Jun.
Article in German | MEDLINE | ID: mdl-24788604

ABSTRACT

This case report describes a patient with keratoconus and neurodermitis suffering from a significantly prolonged postoperative time interval to re-epithelisation after corneal cross-linking. The development of corneal calcifications and vascularisations additionally inhibited proper re-epithelisation. Therefore the patient received four subsequent subconjunctival injections of Bevacizumab and an additional keratectomy to remove the calcifications. This therapeutic scheme led to a significant reduction of corneal vascularisation and finally a full rehabilitation of the epithelium.


Subject(s)
Corneal Neovascularization/chemically induced , Corneal Neovascularization/physiopathology , Cross-Linking Reagents/adverse effects , Cross-Linking Reagents/therapeutic use , Keratoconus/therapy , Neurodermatitis/complications , Postoperative Complications/chemically induced , Postoperative Complications/physiopathology , Re-Epithelialization/drug effects , Re-Epithelialization/physiology , Adult , Antibodies, Monoclonal, Humanized/administration & dosage , Bevacizumab , Calcinosis/chemically induced , Calcinosis/diagnosis , Calcinosis/physiopathology , Calcinosis/therapy , Combined Modality Therapy , Corneal Neovascularization/diagnosis , Corneal Neovascularization/therapy , Humans , Injections, Intraocular , Keratoconus/diagnosis , Male , Neurodermatitis/diagnosis , Photorefractive Keratectomy , Postoperative Complications/therapy , Riboflavin , Slit Lamp
SELECTION OF CITATIONS
SEARCH DETAIL